Heparin-sorbent for low density lipoproteins removal in hypercholesterolemia.
Heparin-sorbent was developed in the USSR Cardiology Research Center for LDL-apheresis in patients with familial hypercholesterolemia. Clinical trials of the sorbent were started in 1985. Heparin-sorbent has a high capacity for LDL. One column (400ml) can remove 3 - 6g of LDL cholesterol, depending on the initial LDL content in the plasma. The sorbent demonstrates a high stability, it can withstand more then 75 sorbtion-desorbtion cycles with only a slight loss of the initial capacity. It means that one column can work for 1,5-2,0 years when used weekly. Heparin-sorbent is the sorbent of limited selectivity, apo-B content in eluate is 40-60% of the total protein content, but it is important that it does not bind HDL.
Sinitsyn
V V
VV
USSR Cardiology Research Center, Moscow.
Metlitscaya
L M
LM
Mamontova
A G
AG
Konovalov
G A
GA
Kukharchuk
V V
VV
D001665:Binding Sites; D002846:Chromatography, Affinity / Q000379:methods; D006493:Heparin / Q000737:chemistry*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification*; D010956:Plasmapheresis / Q000379:methods; D012685:Sepharose; D012965:Sodium Chloride / Q000494:pharmacology
D008077:Lipoproteins, LDL; D012965:Sodium Chloride; D006493:Heparin; D012685:Sepharose